Coherus Oncology Inc
coherus.comWhat Do They Do?
Sells LOQTORZI, a cancer medicine for nasopharyngeal cancer, to wholesalers and distributors, and develops other cancer medicines.
10-K for FY2025, filed Mar 9, 2026We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1…View ↗
On October 27, 2023, we announced that LOQTORZI was approved by the U.S. Food and Drug Administration (“FDA”) in combination with cisplatin…View ↗
We sell and distribute LOQTORZI in the U.S. and Puerto Rico, exclusively through the wholesale (Specialty Distribution) channel. During the…View ↗
How Do They Make Money?
The company sells LOQTORZI to wholesalers and distributors; they typically pay 30 to 80 days after shipment.
10-K for FY2025, filed Mar 9, 2026The Company sells to wholesalers and distributors, (collectively, “Customers”). The Customers then resell to hospitals and clinics…View ↗
-
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗
$42.2M
-
10-K for FY2025, filed Mar 9, 2026
$42.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Toripalimab
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
97% |
Toripalimab, FY2025
$40.8M Sources
|
Sold outright |
|
Other revenue
|
3.2%
FY2022: 0.1%
|
Other revenue, FY2025
$1.3M Sources
|
Who Are Their Customers?
Wholesalers and distributors buy LOQTORZI for resale to hospitals and clinics; the company sells through the wholesale channel in the U.S. and Puerto Rico.
10-K for FY2025, filed Mar 9, 2026
10-K for FY2025, filed Mar 9, 2026
Year Ended December 31, 2025 2024 McKesson Corporation 43 % 43 % Cencora, Inc. 36 % 43 % Cardinal Health, Inc. 20 %…View ↗
Do Revenues Turn Into Profits?
Yes. Its net income in FY2025 was larger than its revenue.
10-K for FY2025, filed Mar 9, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$20.6MView ↗
- ▼ Now a loss
- vs $297.8M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 5, 2026
Open tableView ↗
-
Jun 15, 2026
Changed its independent auditor
The audit committee dismissed Ernst & Young and selected PricewaterhouseCoopers, subject to standard client acceptance procedures.
Sources
8-K, filed Jun 15, 2026
On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed…View ↗
Shrinking. Revenue fell 87% in 4 years, from $326.6M in FY2021 to $42.2M in FY2025, about 40% a year.
From biosimilars to oncology
The company shifted from selling approved biosimilars alongside a toripalimab candidate to commercializing LOQTORZI and developing cancer drug candidates; it says its biosimilar businesses have been divested.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 9, 2026We are a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer…View ↗
Our commercial portfolio includes three FDA-approved biosimilar products. Our first product, UDENYCA® (pegfilgrastim-cbqv), a biosimilar to…View ↗
In addition to our three FDA-approved biosimilar products, we also have an original biologic license application submitted under Section…View ↗
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1…View ↗
We commercialize LOQTORZI in the United States, and we have global rights to develop and commercialize casdozokitug and tagmokitug.View ↗
The UDENYCA Sale represented the last and most significant divestiture of our biosimilar businesses, which comprised the UDENYCA, YUSIMRY…View ↗
Who Do They Compete With?
Competes with Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, EMD Serono, Pfizer, Regeneron, GlaxoSmithKline, BeiGene, Elevar Therapeutics, Akeso Biopharma, Gilead Sciences, Jounce Therapeutics, Shionogi, AbbVie, Bayer, F. Hoffmann-La Roche, Amgen, LaNova Medicines, and Nanjing Immunophage Biotech
10-K for FY2025, filed Mar 9, 2026LOQTORZI faces a competitive market in the United States where a number of anti-PD-1 or PD-L1 antibody drugs have been approved by the FDA…View ↗
Loading...
